Gilgamesh has received a $14 million grant from the National Institute on Drug Abuse to advance the clinical development of their novel cardiac-safe ibogaine.

Cybin (NYSE: CYBN) has been granted a Breakthrough Therapy designation from the FDA for their novel psychedelic molecule CYB003 for Major Depressive Disorder.

Psychedelic biotechnology company MindMed (NASDAQ: MNMD) has received a Breakthrough Therapy designation from the United States FDA for their novel drug MM120.

The United States FDA has granted MDMA assisted therapy a priority review to Lykos Therapeutics.

MAPS has officially launched Lykos Therapeutics as a for profit biotechnology company to advance MDMA assisted therapies.

Psychedelic biotechnology company COMPASS Pathways (NASDAQ:CMPS) has entered into a new multi year research collaboration with Greenbrook TMS (NASDAQ:GNBH).

atai Life Sciences (NASDAQ: ATAI) has announced they will invest $50 million into psychedelic drug developer Beckley Psytech

Silo Pharma (NASDAQ: SILO) has received regulatory approval to advance their novel time release ketamine implant into preclinical research

Incannex Healthcare (NASDAQ: IXHL) subsidiary Clarion Clinics has received regulatory approval to begin to administer psychedelic assisted therapies.

MAPS Public Benefit Corporation has just filed a New Drug Application with the FDA for MDMA assisted therapy to treat post traumatic stress disorder (PTSD).